Key statistics
As of last trade Novocure Ltd (038:DUS) traded at 16.85, -24.60% below its 52-week high of 22.34, set on May 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.00 |
---|---|
High | 16.85 |
Low | 16.00 |
Bid | 16.89 |
Offer | 17.08 |
Previous close | 17.05 |
Average volume | 113.14 |
---|---|
Shares outstanding | 108.20m |
Free float | 98.19m |
P/E (TTM) | -- |
Market cap | 1.89bn USD |
EPS (TTM) | -1.39 USD |
Data delayed at least 15 minutes, as of Nov 11 2024 15:30 GMT.
More ▼
Press releases
- Novocure Appoints Christoph Brackmann as Chief Financial Officer
- Novocure Reports Third Quarter 2024 Financial Results
- Masimo Appoints Timothy Scannell and Wendy Lane to Board of Directors
- FDA Approves Novocure’s Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer
- Novocure to Report Third Quarter 2024 Financial Results
- Novocure to Present Real-World Data at ESMO 2024 Demonstrating Improved Survival Outcomes for Newly Diagnosed Glioblastoma Patients with Increased Use of Tumor Treating Fields (TTFields) Therapy
- Novocure Announces Planned CEO Transition
- Novocure to Participate in 2024 Wells Fargo Healthcare Conference
- Novocure Highlights TTFields Therapy in Treatment of Non-Small Cell Lung Cancer at 2024 World Conference on Lung Cancer
More ▼